tbuckley/cabot-search huggingface dataset:
Changes in Hospital–Physician Affiliations in U.S. Hospitals and Their Effect on Quality of Care
Authors: Kirstin W. Scott, E. John Orav, David M. Cutler, Ashish K. Jha
Journal: Annals of Internal Medicine (2016)

Growing evidence shows that hospitals are increasingly employing physicians.To examine changes in U.S. acute care hospitals that reported employment relationships with their physicians and to determine whether quality of care improved after the hospitals switched to this integration model.Retrospective cohort study of U.S. acute care hospitals between 2003 and 2012.U.S. nonfederal acute care hospitals.803 switching hospitals compared with 2085 nonswitching control hospitals matched for year and region.Hospitals' conversion to an employment relationship with any of their privileged physicians.Risk-adjusted hospital-level mortality rates, 30-day readmission rates, length of stay, and patient satisfaction scores for common medical conditions.In 2003, approximately 29% of hospitals employed members of their physician workforce, a number that rose to 42% by 2012. Relative to regionally matched controls, switching hospitals were more likely to be large (11.6% vs. 7.1%) or major teaching hospitals (7.5% vs. 4.5%) and less likely to be for-profit institutions (8.8% vs. 19.9%) (all P values <0.001). Up to 2 years after conversion, no association was found between switching to an employment model and improvement in any of 4 primary composite quality metrics.The measure of integration used depends on responses to the American Hospital Association annual questionnaire, yet this measure has been used by others to examine effects of integration. The study examined performance up to 2 years after evidence of switching to an employment model; however, beneficial effects may have taken longer to appear.During the past decade, hospitals have increasingly become employers of physicians. The study's findings suggest that physician employment alone probably is not a sufficient tool for improving hospital care.Agency for Healthcare Research and Quality and National Science Foundation Graduate Research Fellowship.
Serological and Molecular Study of Hepatitis E Virus Infections over 2 Years (2013–2015) at Marseille University Hospitals and in Provence-Alpes-Côte D’Azur Region, Southeastern France
Authors: P. Colson, M. Huart, J.-D. Poveda, A. Selles, M. Sicello, C. Dhiver, R. Tola, S. Aherfi, A. Motte, C. Tamalet, V. Moal, R. Gérolami
Journal: Journal of Hepatology (2016)
New systemic treatments to improve survival in melanoma patients whose brain metastases are controlled by an on demand Gamma-knife radiosurgical strategy.
Authors: Jean Jacques Grob, Anne-Sophie Dussouil, Romain Carron, Anderson Loundou, Sandrine Monestier, Marie-Aleth Richard, Caroline Gaudy-Marqueste, Jean Regis
Journal: Journal of Clinical Oncology (2016)

9573 Background: On demand Gamma - knife (OD -GK), ie repeated sessions as many times as required by the appearance of new lesion(s) upon imaging follow-up, is one of the best strategies to control BMs in metastatic melanoma (MM). New systemic treatments (NT) including ipilimumab, anti-PD1 and B-RAF +/- MEK inhibitors (inh) have changed the therapeutic strategies. Nothing is known about a potential additional benefit of NT after the control of BM byOD -GK. Methods: A cohort of 168 mm patients treated by OD -GK between 2010 and 2015, when NTs were introduced step after step in the practice, was retrospectively reviewed. Univariate and multivariate analyses were performed, controlling for a potential selection bias (only best patients receiving NT), including access to NT, LDH, M1c criteria (apart from BM), Karnofsky, number of BMs, need for steroids before 1st GK, age at 1stGK and neurological signs. Results: Among 168 consecutive patients treated withOD -GK, 31.7% had 2 sessions, 21.5% 3 to 7 sessions with a total of 297 sessions targeting 1452 BMs. After 1st GK, 62 patients had access to BRAF+/-MEK inh, 40 to ipilimumab, and 26 to anti-PD1. Median follow-up was 7 months (3-13.5). Median survival post 1st GK was 7.8 months (m) in the whole cohort. It was 13.2 m (HR: 0.43, 0.29-0.63), 12.3 m (HR: 0.63, 0.42-0.95) and median not reached (HR: 0.27, 0.14-0.53), in patients who, after 1st GK, had access to BRAF+/-MEK inh, anti-CTLA4, or anti-PD1, respectively. In multivariate analysis, the access to any type of NT after 1st GK remained significantly associated with higher OS post 1stGK (HR = 0.32, 0.21-0.48); p < 0.001. Conclusions: In mm patients with BMs treated by OD -GK, the introduction of NT after GK was associated with a prolonged survival. Direct BM control by GK, followed by NT especially anti-PD1 seems to favor long survival in patients with melanoma BMs.
The Ex-Vivo Tolerance Induction To TLR7 In Donor Lymphocytes Prevents aGvHD In a Mismatched Transplantation Mouse Model
Authors: Nikolaos Zogas, Stylianos Malasidis, Fotios Iordanidis, Garyfalia Karponi, Eleftheria Tsolaki, Zaharias Scouras, Achilles Anagnostopoulos, Evangelia Yannaki
Journal: Blood (2013)
Long-Term Survival Analysis in Older Patients with AML Treated Intensively: Positive Impact of Idarubicin in a Cure Fraction Estimation Model.
Authors: Hervé Dombret, Claude Gardin, Sylvie Chevret, Cecile Pautas, Pascal Turlure, Xavier Thomas, Bruno Quesnel, Thierry de Revel, Christine Terré, Pierre Fenaux, Dominique Bordessoule, Sylvie Castaigne
Journal: Blood (2008)
The Tolerability of SOF/VEL for 12 Weeks in &gt;1,000 Patients Treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies: An Integrated Safety Analysis
Authors: I. Jacobson, N. Brau, S. Bourgeois, P. Mathurin, P. Thuluvath, W.J. Fessel, S. Ryder, G. Gerken, L. Liu, X. Ding, J. McNally, A. Osinusi, D. Brainard, M. Subramanian, G. Foster
Journal: Journal of Hepatology (2016)
Single Cell Analyses Demonstrate No Up-Regulation of Human Innate Genes in HDV Mono-Infected Human Hepatocytes
Authors: K. Giersch, T. Volz, L. Allweiss, J. Kah, A.W. Lohse, J. Petersen, M. Dandri, M. Lütgehetmann
Journal: Journal of Hepatology (2016)
Evidence-Based Guideline: The USPSTF recommends screening for colorectal cancer in adults 50 to 75 years of age
Authors: Ronald L. Koretz
Journal: Annals of Internal Medicine (2016)

Source Citation Lin JS, Piper MA, Perdue LA, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;315:2576-94. 27305422
Autologous Stem Cell Transplantation with Bendaeam (Bendamustine, Etoposide, Cytarabine, Melphalan) As Conditioning Regimen for Non-Hodgkin’s Lymphoma and Hodgkin’s Lymphoma
Authors: Sylvain Garciaz, Diane Coso, Florence Broussais, Jean-Marc Schiano, Boris Calmels, Colombe Saillard, Lauris Boudin, Sophie Amrane, Didier Blaise, Reda Bouabdallah
Journal: Blood (2014)
C-Edge Co-Star: Favorable Impact of Elbasvir and Grazoprevir on Health-Related Quality of Life in Treatment-Naïve HCV-Infected Persons who Inject Drugs Receiving Opioid Agonist Therapy
Authors: J.M. Arduino, O. Shibolet, A.H. Litwin, J. Grebeley, F. Altice, C. Nwankwo, T.C. Mast, Z. Jiang, I.N. Gendrano, H.L. Platt, G.J. Dore
Journal: Journal of Hepatology (2016)
Coagulation of Patients with Cirrhosis Revisited Using an Assay Taking into Account Endothelial Cells: Thrombin Generation is Quicker butless Abundant
Authors: P.-E. Rautou, C. Kuadjovi, L. Elkrief, L. Venisse, L. Boudaoud, F. Durand, D. Valla, N. Ajzenberg, E. De Raucourt
Journal: Journal of Hepatology (2016)
Immature monocytes contribute to cardiopulmonary bypass-induced acute lung injury by generating inflammatory descendants
Authors: Zhichen Xing, Junyan Han, Xing Hao, Jinhong Wang, Chunjing Jiang, Yu Hao, Hong Wang, Xueying Wu, Liwei Shen, Xiaojun Dong, Tong Li, Guoli Li, Jianping Zhang, Xiaotong Hou, Hui Zeng
Journal: Thorax (2016)

As immune regulatory and effector cells, monocytes play an important role in the blood-extracorporeal circuit contact-related acute lung injury in patients undergoing cardiopulmonary bypass (CPB). However, circulating monocytes are phenotypically and functionally heterogeneous, so we characterised how immature monocytes affect acute lung injury induced by CPB.The identification and dynamic changes in monocyte subsets were monitored by flow cytometry in patients undergoing CPB and in a rat model of CPB. The differentiation and migration of monocyte subsets were explored by in vitro cultures and adoptive transfer in the CPB rat model.We observed a dramatic increase of two monocyte subsets in the peripheral blood of patients undergoing CPB, involving tumour necrosis factor (TNF)-α-producing, mature intermediate CD14highCD16+ monocytes and a novel immature CD14lowCD16- subset. The immature CD14lowCD16- monocytes possessed limited ability for TNF-α production, and failed to suppress T-cell proliferation mediated by T-cell receptor signalling. However, these immature cells were highly proliferative and could differentiate into TNF-α producing, mature CD14highCD16+ monocytes. In the rat model of CPB, we further demonstrated that CPB induced migration of immature monocytes into the lungs, either from the bone marrow or from the spleen. Moreover, we confirmed the hypothesis that immature subsets could contribute to CPB-induced acute lung injury by giving rise to TNF-α producing descendants.The immature CD14lowCD16- monocytes might contribute to blood-circuit contact-induced acute lung injury by generating TNF-α-producing, mature monocytes. New strategies based on monocyte manipulation could be a promising therapeutic approach for minimising CPB-related lung injury.
Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma
Authors: Christof Scheid, Pieter Sonneveld, Ingo Schmidt-Wolf, Bronno van der Holt, Thomas Hielscher, Laila el Jarari, Uta Bertsch, Hans Salwender, Sonja Zweegman, Mathias Hänel, Edo Vellenga, Joerg Schubert, Igor Wolfgang Blau, Asiong Jie, Helgi Van de elde, Norma Peter, Martijn Schaafsma, Walter Lindemann, Marie Jose Kersten, Ulrich Duehrsen, Michel Delforge, Katja Weisel, Sandra Croockewit, Hans Martin, Shulamit Wittebol, Harry Schouten, Marinus van Marwijk-Kooy, Pierre Wijermans, Henk M Lokhorst, Hartmut Goldschmidt
Journal: Blood (2010)
P0867 : Efficacy evaluation of 24 week SOF + RBV in a heterogeneous, real-world population of genotype 3 HCV patients; Data from the trio network
Authors: K. Kowdley, B. Bacon, D. Dieterich, E. Lawitz, S. Milligan, N. Tsai, Z. Younossi, S. Flamm
Journal: Journal of Hepatology (2015)
Phase II prospective study of radiosurgery for multiple CNS metastatic disease.
Authors: Greg J. Kubicek, Tamara A. LaCouture, Alan Turtz, Ashish Bharat Patel, Lesley Hughes, Anne Bexon, Jinyu Xue, Micheal Choi, Piya V Saraiya, Nati Lerman, Sucha O. Asbell, Howard Warren Goldman
Journal: Journal of Clinical Oncology (2015)

e20555 Background: Treatment for CNS metastatic disease for 1-4 metastatic lesions can include whole brain radiation (WBRT) or stereotactic radiosurgery (SRS).SRS in the setting of CNS 1-4 mets has advantages over WBRT including shorter treatment time and less toxicity. For patients with more than 4 lesions the current standard is for WBRT. This is a phase II study evaluating SRS in the treatment of multiple CNS mets (5-25), primary endpoint is survival and secondary endpoints include CNS failure, QOL (FACT-Br), and neurocognition (MOCA). Methods: Eligible patients had CNS metastatic disease with 5-25 CNS metastatic sites. This is the planned interim analysis for the first 17 patients enrolled of a total planned 33 patients. Median age is 65 years, 11 females, 11 (64%) patients with NSCLC, 2 patients had previous WBRT. 6 patients have a KPS of 60, while the remainder have KPS 70 or greater. Recursive partitioning analysis (RPA) category 1,2,3 was 2, 9, 6 patients respectively. The median number of treated CNS lesions was 10 (range 4 to 34, intent to treat). Results: median follow-up for all patients is 165 days and for surviving patients 239 days. Median survival is 318 days. 4 patients had subsequent CNS failure elsewhere in the brain; no patients had failure at a treated site. Neurocognitive and QOL scores at last follow-up were unchanged compared to prior to treatment. Using RPA survival as a historical control, patients on protocol had significantly improved OS (P < 0.03). Conclusions: In this planned interim analysis of patients with multiple CNS mets (defined as 5-25) treated with SRS we found excellent survival rates in addition to preserved neurocognitive function and QOL. We feel that SRS is a safe and effective treatment for patients with multiple CNS mets and plan to continue accrual to this phase II study.
Prevalence and Impact of Baseline Resistance-Associated Variants on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir against GT1 HCV Infection: Hcv-Target Interim Analysis
Authors: G.P. Wang, J.D. Reeves, N. Terrault, J.K. Lim, G. Morelli, A. Kuo, J. Levitsky, K. Sherman, L.M. Frazier, A. Ramani, J. Peter, L. Akuskevich, M.W. Fried, D.R. Nelson
Journal: Journal of Hepatology (2016)
Diagnosing Traumatic Encephalopathy Syndrome—Reply
Authors: Nicole Reams, Matthew L. Lorincz, Jeffrey S. Kutcher
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Frequency, Patient Characteristics, and Outcomes of Mild to Moderate Heart Failure Complicating ST-Segment Elevation Acute Myocardial Infarction: Lessons from Four International Fibrinolytic Therapy Trials
Authors: D Hasdai, EJ Topol, R Kilaru, A Battler, ML Simoons, RA Harrington, A Vahanian, EM Ohman, CB Granger, Frans Van de Werf, CM O'connor, Holmes
Journal: Circulation (2001)
Quick Sepsis-related Organ Failure Assessment, Systemic Inflammatory Response Syndrome, and Early Warning Scores for Detecting Clinical Deterioration in Infected Patients outside the Intensive Care Unit
Authors: Matthew M. Churpek, Ashley Snyder, Xuan Han, Sarah Sokol, Natasha Pettit, Michael D. Howell, Dana P. Edelson
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

The 2016 definitions of sepsis included the quick Sepsis-related Organ Failure Assessment (qSOFA) score to identify high-risk patients outside the intensive care unit (ICU).We sought to compare qSOFA with other commonly used early warning scores.All admitted patients who first met the criteria for suspicion of infection in the emergency department (ED) or hospital wards from November 2008 until January 2016 were included. The qSOFA, Systemic Inflammatory Response Syndrome (SIRS), Modified Early Warning Score (MEWS), and the National Early Warning Score (NEWS) were compared for predicting death and ICU transfer.Of the 30,677 included patients, 1,649 (5.4%) died and 7,385 (24%) experienced the composite outcome (death or ICU transfer). Sixty percent (n = 18,523) first met the suspicion criteria in the ED. Discrimination for in-hospital mortality was highest for NEWS (area under the curve [AUC], 0.77; 95% confidence interval [CI], 0.76-0.79), followed by MEWS (AUC, 0.73; 95% CI, 0.71-0.74), qSOFA (AUC, 0.69; 95% CI, 0.67-0.70), and SIRS (AUC, 0.65; 95% CI, 0.63-0.66) (P < 0.01 for all pairwise comparisons). Using the highest non-ICU score of patients, ≥2 SIRS had a sensitivity of 91% and specificity of 13% for the composite outcome compared with 54% and 67% for qSOFA ≥2, 59% and 70% for MEWS ≥5, and 67% and 66% for NEWS ≥8, respectively. Most patients met ≥2 SIRS criteria 17 hours before the combined outcome compared with 5 hours for ≥2 and 17 hours for ≥1 qSOFA criteria.Commonly used early warning scores are more accurate than the qSOFA score for predicting death and ICU transfer in non-ICU patients. These results suggest that the qSOFA score should not replace general early warning scores when risk-stratifying patients with suspected infection.
Regional wall motion and coronary patency rate after intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA): long-term results
Authors: Machino Takeshi, Tada Hiroshi, Sekiguchi Yukio, Naruse Yoshihisa, Ozawa Mahito, Yamasaki Hiro, Igarashi Miyako, Kuroki Kenji, Itoh Yoko, Kuga Keisuke, Aonuma Kazutaka
Journal: Circulation (1986)
The rate of meiotic gene conversion varies by sex and age
Authors: Bjarni V Halldorsson, Marteinn T Hardarson, Birte Kehr, Unnur Styrkarsdottir, Arnaldur Gylfason, Gudmar Thorleifsson, Florian Zink, Adalbjorg Jonasdottir, Aslaug Jonasdottir, Patrick Sulem, Gisli Masson, Unnur Thorsteinsdottir, Agnar Helgason, Augustine Kong, Daniel F Gudbjartsson, Kari Stefansson
Journal: Nature Genetics (2016)
Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis
Authors: R.J. Thorneloe, C. Bundy, C.E.M. Griffiths, D.M. Ashcroft, L. Cordingley
Journal: British Journal of Dermatology (2016)

Medication nonadherence is known to limit the effectiveness of available therapies; however, little is known specifically about medication adherence in people with psoriasis. Medicines self‐management can feel onerous to those with dermatological conditions due to the nature of therapies prescribed and many individuals with psoriasis experience additional challenges such as physical and psychological comorbidities that place significant additional demands on individuals and may undermine adherence. Viewing nonadherence to medication as an outcome of limited personal coping resources and conflicting goals may help to explain medication nonadherence. To explore individuals' perspectives of their psoriasis, medication and its management. Twenty people with psoriasis were recruited from community samples in England and interviewed in‐depth about their perceptions of their psoriasis, medication, and adherence to medication and self‐management advice. Data were analysed using Framework Analysis. Participants reported that adhering to recommended treatment regimens conflicted with the management of the physical and psychological demands of living with psoriasis. Medication usage was viewed as a source of unresolved emotional distress and, for some, resulted in poor self‐reported adherence, which included medication overuse, underuse and rejection of prescribed therapies. Perceived lack of engagement by clinicians with participants' self‐management difficulties was viewed as an additional source of stress and distress. Adhering to medication in psoriasis can be an additional source of considerable emotional distress. We interpreted some episodes of nonadherence to psoriasis medication as rational attempts by individuals to minimize distress and to gain control over their life.
The Mucus Barrier to Inhaled Gene Therapy
Authors: Gregg A Duncan, James Jung, Justin Hanes, Jung Soo Suk
Journal: Molecular Therapy (2016)

Recent evidence suggests that the airway mucus gel layer may be impermeable to the viral and synthetic gene vectors used in past inhaled gene therapy clinical trials for diseases like cystic fibrosis. These findings support the logic that inhaled gene vectors that are incapable of penetrating the mucus barrier are unlikely to provide meaningful benefit to patients. In this review, we discuss the biochemical and biophysical features of mucus that contribute its barrier function, and how these barrier properties may be reinforced in patients with lung disease. We next review biophysical techniques used to assess the potential ability of gene vectors to penetrate airway mucus. Finally, we provide new data suggesting that fresh human airway mucus should be used to test the penetration rates of gene vectors. The physiological barrier properties of spontaneously expectorated CF sputum remained intact up to 24 hours after collection when refrigerated at 4 °C. Conversely, the barrier properties were significantly altered after freezing and thawing of sputum samples. Gene vectors capable of overcoming the airway mucus barrier hold promise as a means to provide the widespread gene transfer throughout the airway epithelium required to achieve meaningful patient outcomes in inhaled gene therapy clinical trials. Recent evidence suggests that the airway mucus gel layer may be impermeable to the viral and synthetic gene vectors used in past inhaled gene therapy clinical trials for diseases like cystic fibrosis. These findings support the logic that inhaled gene vectors that are incapable of penetrating the mucus barrier are unlikely to provide meaningful benefit to patients. In this review, we discuss the biochemical and biophysical features of mucus that contribute its barrier function, and how these barrier properties may be reinforced in patients with lung disease. We next review biophysical techniques used to assess the potential ability of gene vectors to penetrate airway mucus. Finally, we provide new data suggesting that fresh human airway mucus should be used to test the penetration rates of gene vectors. The physiological barrier properties of spontaneously expectorated CF sputum remained intact up to 24 hours after collection when refrigerated at 4 °C. Conversely, the barrier properties were significantly altered after freezing and thawing of sputum samples. Gene vectors capable of overcoming the airway mucus barrier hold promise as a means to provide the widespread gene transfer throughout the airway epithelium required to achieve meaningful patient outcomes in inhaled gene therapy clinical trials.
Reduced Natural Killer Function Accompanies MDS Disease Progression and Is Restored by Lenalidomide (CC5013, Revlimid®) Via a Mechanism Divergent from Interleukin-2 (IL-2).
Authors: P.K. Epling-Burnette, Fanqi Bai, Jeffrey S. Painter, Rollison Dana, JianXiang Zou, Edna Ku, Bin Zhong, Sheng Wei, Julie Y. Djeu, Alan F. List
Journal: Blood (2006)
Asymptomatic Intracranial Hemorrhage Among Japanese Patients Taking Edoxaban for Non-Valvular Atrial Fibrillation.
Authors: Masahiro Yasaka, Hiroshi Inoue, Yohko Kawai, Takenori Yamaguchi, Shinichiro Uchiyama, Masayasu Matsumoto, Satoshi Ogawa, Yukihiro Koretsune, Takeshi Yamashita
Journal: Blood (2009)
Endotoxaemia is Associated with Histological Severity of Non-Alcoholic Fatty Liver Disease and may be Increased in Patients with the TM6SF2 Gene Variants
Authors: V.W.-S. Wong, G.L.-H. Wong, J. Pang, A.W.-H. Chan, H.-Y. Chan, C.-H. Tse, S.S.-T. Shu, H.L.-Y. Chan
Journal: Journal of Hepatology (2016)
Long-Term Outcome in Liver Transplantation Candidates with Portopulmonary Hypertension
Authors: L. Savale, C. Sattler, Y. Calmus, C. Duvoux, F. Durand, F. Conti, C. Feray, C. Francoz, P. Hervé, D. Samuel, J.C. Duclos-Vallée, O. Sitbon
Journal: Journal of Hepatology (2016)
Cardiomyocyte-restricted nitric oxide synthase 3 overexpression attenuates left ventricular remodeling in mice with chronic pressure overload
Authors: DS Jassal, ES Buys, G Neilan, MJ Raher, F Ichinose, Stefan Janssens, MH Picard, KD Bloch, M Scherrer-Crosbie
Journal: Circulation (2005)